Is the Neurotechnology Market growing now?
In our neurotechnology market deck, you will find everything you need to understand the market
SUMMARY
Is the Neurotechnology Market growing now? Yes, the neurotechnology market is growing right now, but the growth is uneven and concentrated in clinical, reimbursed, and near-reimbursed use cases.
The market is hard to read because the strongest signals do not all point in the same direction. BCI funding, FDA movement, hospital adoption, reimbursement pressure, and public funding are moving at different speeds.
The cleanest growth evidence comes from medical neurotechnology already tied to doctors, procedures, reimbursement, and installed systems. BrainsWay, NeuroPace, Boston Scientific, Flow, Neurolief, and Abbott show more measurable traction than the most futuristic BCI stories.
BCI is not weak, but it is growing like an option market rather than a revenue market. Investors are funding future clinical categories, neural data assets, decoding models, and implant workflows more than current customer demand.
Analyst forecasts look bullish, but they are not enough on their own. The problem is that “neurotechnology” can mean BCI, neuromodulation, neurodiagnostics, surgical tools, cochlear-related systems, or several of these at once.
Depression neurotechnology looks like one of the clearest breakout pockets. Clinic TMS is expanding capacity, while FDA-approved at-home stimulation could attack the repeated-visit bottleneck that has limited access.
Pain and epilepsy are still doing much of the commercial heavy lifting. That matters because the neurotechnology market’s current center of gravity is chronic disease management, not consumer brain gadgets or mass-market thought-to-text devices.
Reimbursement is the biggest brake on growth. Inspire Medical’s 2026 guidance reset shows how quickly a procedure-based neurostimulation business can slow when coding, authorization, or payer mechanics shift.
FDA activity is making the market more investable, but not all regulatory milestones are equal. A PMA-approved depression device is closer to revenue than an early feasibility BCI trial or a component clearance.
Large medtech companies are still interested, but selectively. Boston Scientific’s pain-related acquisitions and supplier consolidation point to real demand, while Nevro’s sale shows that standalone neurodevice companies can still get squeezed.
China is increasing urgency in BCI more than it is proving broad commercialization. Human implants, policy support, hospital coordination, and capital could compress timelines, but public “brain chip” claims still need careful scrutiny.
The key conclusion is that neurotechnology is not in a simple hype cycle or a simple downturn. The market is selecting winners: companies with evidence, reimbursement, distribution, regulatory clarity, and proprietary neural data are moving forward, while weaker or more exposed models are under pressure.
This market map, featured in our neurotechnology market deck, highlights top companies and startups in the neurotechnology market
Why is the neurotechnology market so hard to read right now?
It’s because the neurotechnology market is not giving one clean signal right now.
First, there are a lot of positive and recent signals.
In the last 9 to 12 months, we found large BCI financings, FDA movement, real neuromodulation revenue growth, new at-home depression neurostimulation approvals, and continued expansion by large medtech companies. Synchron raised $200 million in November 2025. Merge Labs raised $252 million in January 2026. NeuroPace raised 2026 revenue guidance after a 19.5% Q1 increase in RNS System revenue. BrainsWay shipped a record 117 Deep TMS systems in Q1 2026. Flow and Neurolief both moved at-home depression neuromodulation through FDA approval pathways.
But the negative case is also here.
Inspire Medical’s Q1 2026 revenue grew only 1.6%, and the company cut full-year guidance by more than $100 million because reimbursement friction hit procedure flow. Neuronetics grew total revenue, but U.S. treatment-session revenue declined. Nevro had to sell to Globus Medical after pressure in spinal cord stimulation. NIH BRAIN Initiative funding dropped from $402 million in FY2024 to $321 million in FY2025, showing that public research funding is not a straight upward line. And BCI, the loudest part of the market, is still mostly investigational rather than revenue-generating.
Are analysts too bullish on the neurotechnology market?
Today, analysts look broadly bullish on the neurotechnology market, but their numbers hide very different markets.
Mordor Intelligence estimates the neurotechnology market at $17.84 billion in 2026, up from $15.77 billion in 2025, with a 13.12% CAGR to 2031. Fortune Business Insights estimates $19.19 billion in 2026 and a 7.0% CAGR through 2034. Research and Markets puts the market at $19.84 billion in 2026, growing 14.1% to 2030. IMARC starts lower, at $13.9 billion in 2025, but still expects a 9.61% CAGR through 2034.
That looks like consensus growth. But we should not overread it.
Some reports include neuromodulation, neurodiagnostics, cochlear-related systems, surgical tools, and brain-interface devices. Others isolate BCI or neuromodulation. That is why Mordor’s 2026 BCI estimate is around $1.33 billion, while Grand View Research puts 2026 neuromodulation devices around $7.0 billion. These are not just different estimates but, actually, different baskets.
The consensus says the market should expand in 2026, but analysts are mostly describing the long-cycle medtech installed base, not the messy month-by-month reality of reimbursement, procedure volume, trials, and capital concentration. Analyst forecasts are a good first layer.
They cannot be the core evidence. We need to study real signals and this is what we will do now.
If you want more recent data on this point, please see our latest neurotechnology market report.
As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily
Are BCI startups getting funded because demand is real?
BCI funding is real, but it is actually funding future clinical optionality more than current customer demand.
The recent capital signal is unusually large.
Synchron raised $200 million in November 2025 to advance Stentrode commercialization and AI operations. Merge Labs raised $252 million in January 2026 from OpenAI, Bain Capital, Gabe Newell, and others to pursue ultrasound-based non-invasive BCI. Neuralink reportedly raised $600 million in 2025 at a $9 billion pre-money valuation. Inside BCI estimated that the sector raised more than $960 million across at least nine significant rounds in Q1 2026.
When you think of it, that is a lot for a category with very little commercial BCI revenue.
Clearly, investors are not underwriting current sales but a race to own neural data, decoding models, implant workflows, and future clinical markets such as communication restoration, paralysis, depression, memory loss, and sensory repair.
This is why the signal is both bullish and fragile.
It proves investor appetite is increasing but it does not prove the BCI market is already monetizing.
Are hospitals actually using more medical neurotechnology?
Hospitals and clinics are using more medical neurotechnology, but mainly where reimbursement and workflows already exist.
The cleanest signal is not BCI but, actually, reimbursed neurostimulation.
BrainsWay shipped 117 Deep TMS systems in Q1 2026, up 44% year over year, and reached an installed base of about 1,820 systems. NeuroPace reported $21.7 million of RNS System revenue in Q1 2026, up 19.5%. Boston Scientific’s Q1 2026 neuromodulation performance was reported as strong, helped by pain-management assets such as Nalu and Intracept. These are provider-side adoption signals, not just investor decks.
The order of magnitude matters. A record quarter of 117 TMS systems is meaningful because it expands clinic capacity. NeuroPace’s raised guidance matters because epilepsy implants are not impulse purchases: they require specialist centers, patient selection, surgery, and follow-up. Boston Scientific matters because large medtech revenue is exposed to real procedure volumes, not future TAM slides.
But this growth is not universal. Inspire Medical shows how quickly a procedure-based neurostimulation business can slow when payment mechanics change. So the hospital signal is: adoption is growing where the product is clinically validated, reimbursed, and operationally familiar.
The market is not yet broad enough to absorb reimbursement shocks everywhere.
This chart, featured in our neurotechnology market deck, shows annual VC investment in neurotechnology startups
Is depression neurotechnology finally moving beyond clinics?
Depression neurotechnology is one of the strongest current growth pockets because it is moving from clinic-only treatment toward supervised home use.
BrainsWay’s Q1 2026 numbers show clinic-side demand: 35% revenue growth, 117 Deep TMS systems shipped, and remaining performance obligations up 25% to roughly $75 million. That is not just more awareness. Rather, it suggests provider networks are adding equipment and committing to future usage.
The newer signal is home-based neuromodulation. Flow Neuroscience’s FL-100 received FDA PMA approval in December 2025 for moderate to severe major depressive disorder, either as monotherapy or adjunctive treatment. Flow says U.S. availability is expected in September 2026. Neurolief’s ProlivRx also received FDA PMA approval in January 2026 for adults with MDD who did not respond adequately to at least one antidepressant, and BrainsWay had a strategic investment in Neurolief.
So it looks like the category is splitting into two access models: high-capacity clinic TMS and prescription-supervised home stimulation. That can expand the market because it attacks the biggest bottleneck in brain stimulation: repeated clinic visits.
If you want more recent data on this point, please see our latest neurotechnology market report.
Are pain and epilepsy neurodevices still doing the heavy lifting?
To this day, pain and epilepsy neurodevices are indeed still carrying the commercial neurotechnology market.
NeuroPace is a strong epilepsy signal. In Q1 2026, RNS System revenue grew 19.5%, and the company raised full-year revenue guidance to $99 million to $101 million. Management also assumed 21% to 23% growth in core RNS revenue from existing indications, excluding potential upside from idiopathic generalized epilepsy expansion. That matters because it tells us the base market is expanding before the next indication is counted.
Pain is more mixed, but still large. Grand View Research estimates neuromodulation devices at $7.0 billion in 2026. MarketsandMarkets projects neuromodulation growing from $6.81 billion in 2025 to $10.68 billion by 2030. Abbott released five-year evidence in January 2026 on BurstDR and dorsal root ganglion stimulation reducing pain-related healthcare visits. Boston Scientific’s neuromodulation growth also suggests pain-procedure demand remains resilient.
The commercial center of gravity is therefore not futuristic BCI but rather chronic disease management.
This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology
Are payers quietly slowing neurotechnology down?
Payers are clearly the biggest brake on neurotechnology growth right now.
The clearest warning is Inspire Medical. In Q1 2026, revenue rose only 1.6% to $204.6 million, and the company cut 2026 guidance from $950 million–$1 billion to $825 million–$875 million. Coverage of the quarter tied the reset to coding and reimbursement disruption, including WISeR-related Medicare authorization pressure and the transition around Inspire V procedure coding.
This is not a small signal. A guidance cut of more than $100 million means the bottleneck was not just “patients want less therapy.” It means the payment path changed enough to affect procedure timing, physician economics, and company revenue visibility.
Neuronetics gives a smaller but useful second warning. Q1 2026 total revenue grew 8%, but U.S. treatment-session revenue declined from $9.6 million to $9.1 million.
That tells us installed systems or clinics can grow while utilization quality weakens.
If you want more recent data on this point, please see our latest neurotechnology market report.
Are BCI clinical trials moving fast enough to create a market?
BCI clinical trials are moving faster, but still not fast enough to make BCI a broad commercial market today.
The trial pipeline is clearly more active.
Neuralink’s PRIME study is recruiting and evaluates its N1 implant and R1 surgical robot in people with tetraparesis or tetraplegia. Paradromics received FDA IDE approval in November 2025 for the Connect-One early feasibility study, focused on speech restoration and computer control. ClinicalTrials.gov describes Connect-One as a study for patients with severe motor impairment who need assistive communication or computer-device control. INBRAIN Neuroelectronics completed enrollment in April 2026 for its first-in-human graphene neural-interface study.
That is real progress because BCI companies are moving from lab demonstrations into named human protocols. But trial speed should be judged against medtech commercialization reality. Early feasibility studies are not pivotal trials. Recruitment at major centers is not commercial availability. A 30-day cleared cortical array is not a full implantable consumer BCI.
So the BCI market is expanding at the pipeline level. It is not yet expanding like a product market. The current market signal is something like “more shots on goal,” not “more paying customers.”
This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups
Are FDA approvals making neurotechnology more investable?
Yes, recently, FDA activity has been making clinical neurotechnology more investable, especially where the approval creates a real use case.
Precision Neuroscience received FDA 510(k) clearance in April 2025 for its Layer 7 Cortical Interface, a high-resolution cortical electrode array authorized for recording, monitoring, and stimulation on the brain surface for up to 30 days.
That is not a full commercial BCI, but it gives a core component a real regulatory status.
Paradromics’ IDE approval is also significant because it targets speech restoration with a fully implantable BCI. Flow and Neurolief are even closer to market because their approvals relate to treatment devices for depression, not just BCI components or early feasibility trials. Nia Therapeutics received FDA Breakthrough Device designation in March 2026 for an AI-guided brain implant for TBI-related memory loss.
The pattern is stronger than one clearance. FDA movement is spreading across cortical interfaces, fully implantable BCIs, home depression stimulation, and AI-guided closed-loop therapy.
That makes the sector more credible to investors because the field now has multiple regulatory paths.
Are big medtech companies still buying into neurotechnology?
Large medtech companies are still buying into neurotechnology, but they are buying selectively.
Boston Scientific is the best example of expansion by acquisition. Relievant gave it the Intracept basivertebral nerve ablation system. Nalu added peripheral nerve stimulation. Those assets were still relevant to its 2026 neuromodulation performance, which suggests the company is getting strategic value from neuro-adjacent pain assets rather than just collecting brands.
Globus Medical’s acquisition of Nevro is the opposite signal, but still useful. Nevro’s sale reflected pressure in standalone spinal cord stimulation, not category euphoria. Yet once inside Globus, Nevro contributed about $99 million in Q3 2025 sales and was reported as accretive faster than expected. That implies the asset still had commercial value when paired with a larger platform.
Supplier-side consolidation also matters. Resonetics agreed to acquire Resolution Medical in early 2026, explicitly adding capabilities in neuromodulation and structural heart. This is a quieter signal than a flashy BCI round, but it shows that manufacturing and development suppliers expect enough device demand to justify expanding capacity.
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms
Is China making the neurotechnology market move faster?
It’s more subtle than that: China is making the BCI part of neurotechnology feel more urgent.
Recent reporting says NeuroXess has advanced invasive human BCI trials and enabled cursor control within days after implantation. The same coverage links China’s acceleration to government support, investor enthusiasm, and a national push to become a global BCI leader by 2030. Separately, June 2026 coverage reported Chinese activity around NEO, a brain-chip system tied to Tsinghua University and Neuracle Technology, for paralysis and spinal cord injury applications.
We should be careful with “commercial brain chip” claims because public reporting can run ahead of regulatory detail. But the competitive signal is still important. BCI progress depends on human implants, clinical follow-up, surgical learning curves, and longitudinal neural datasets. A country that can coordinate policy, hospitals, and capital may compress timelines faster than a purely venture-led U.S. model.
Is consumer neurotechnology still mostly smoke?
Consumer neurotechnology is still the weakest part of the market story.
We found attention-grabbing claims, but not enough independent validation.
Sabi’s 2026 claims around caps and beanies with 70,000 to 100,000 sensors that can translate thought to text are a good example. The claim is exciting, but recent coverage also notes that few independent reviewers have tested the technology. That matters because non-invasive BCI has a hard physics problem: signal quality outside the skull is much weaker than implanted recordings.
Neurable’s $35 million Series A in December 2025 shows there is still funding for “everyday BCI” and brain-signal translation in consumer-like devices. But this is not the same quality of evidence as BrainsWay shipments or NeuroPace implant revenue. Funding proves investor appetite; it does not prove mass consumer adoption.
The consumer market may eventually matter, especially through earbuds, headphones, sleep devices, gaming, and mental-performance products.
Right now, though, consumer neurotech is not the evidence base for current market growth.
This chart, featured in our neurotechnology market deck, breaks down revenue by customer segment in the neurotechnology market
Are governments still funding neurotechnology like a priority?
Government support is present, but the public-funding signal is not uniformly bullish.
NIH BRAIN Initiative funding is the clearest reality check. The FY2025 budget was $321 million, down from $402 million in FY2024 and far below the $680 million level in FY2023, largely because 21st Century Cures Act funding stepped down. That is not a collapse of neuroscience, but it shows the public R&D base has been under budget pressure.
There are still support signals. DARPA’s N3 program continues to frame non-surgical neurotechnology as strategically important for brain-machine interfaces. The Transmitter reported in early 2026 that the final 2026 spending plan included a 33% boost to the BRAIN Initiative, though it also noted multiyear funding mechanics could limit grant flow. NeurAxis also secured a VA Federal Supply Schedule contract effective December 2025 for IB-Stim, broadening access through a federal procurement channel.
So public support is not disappearing. But it is uneven.
Are neural-data and AI startups changing the market logic?
AI is indeed changing the neurotech market logic. It’s partly because neural data is becoming the scarce asset.
The best-funded BCI companies are not just selling electrodes. They are also trying to build data loops. Synchron’s financing materials emphasized AI and engineering expansion. Merge Labs is explicitly built around ultrasound, molecular interfaces, and AI interpretation. Precision has discussed the value of large neural datasets for future decoding models. Nia Therapeutics’ Breakthrough-designated memory implant uses AI-guided personalized stimulation across multiple brain regions.
The technical literature supports why investors care. In 2025, research on real-time brain-to-voice neuroprosthesis showed that neural decoding can produce more natural communication for people with severe paralysis. Stanford’s inner-speech work also showed progress in decoding imagined speech while highlighting privacy safeguards.
So, neurotechnology is becoming less like a pure hardware market and more like a clinical data-and-model market. This helps explain why AI investors are entering.
But it also raises the bar: companies without proprietary neural data, regulated access, or strong decoding performance may look much less valuable.
This chart, featured in our neurotechnology market deck, shows how brain sensing wearable technology has evolved over time
Are neurotechnology companies hiring, or just announcing visions?
Hiring signals look positive for top BCI and neural-interface companies, but not broad enough to prove market-wide acceleration.
Neuralink reportedly expanded production and manufacturing ambitions around high-volume chip production and surgical automation. Merge Labs entered 2026 with a very large seed round and public hiring posture around non-invasive brain interfaces. Synchron’s $200 million round explicitly mentioned expanding AI and engineering operations in New York and San Diego. Neurosoft Bioelectronics raised $7.5 million in May 2026 to advance stretchable, non-penetrating implants and a neural data platform, which is small but relevant because it points to hiring around materials, cortical recording, and AI-model training.
The hiring signal is useful because it shows what companies are spending on: manufacturing, AI, clinical operations, and neural-interface engineering. Those are commercialization capabilities, not just research roles.
But the signal is selective. We do not see a broad “everyone in neurotech is hiring” boom yet.
If you want more recent data on this point, please see our latest neurotechnology market report.
Are companies in neurotechnology under pressure right now?
Definitely yes, several neurotechnology companies are under pressure right now.
Nevro’s sale to Globus Medical is the clearest sign. A once-prominent spinal cord stimulation company sold for about $250 million after commercial pressure.
That is not a healthy standalone growth story. It shows that even clinically accepted neurostimulation categories can become difficult when competition, sales execution, and procedure economics tighten.
Inspire Medical’s 2026 reset is another major pressure signal. As seen above, its Q1 slowdown was not a small miss; the company materially reduced its full-year outlook after reimbursement disruption. Neuronetics also shows pressure below the headline because treatment-session revenue declined despite total revenue growth, and external analysis pointed to margin compression and leverage concerns.
This does not mean the market is shrinking. Rather, it means the market is selecting winners.
Neurotechnology companies with evidence, reimbursement, distribution, and capital are moving forward. Companies exposed to one product, one payer pathway, or one procedure bottleneck can get hit quickly.
In our neurotechnology market deck, we identify pain points entrepreneurs should prioritize
So, is the neurotechnology market growing right now?
The neurotechnology market is growing right now, but it is not growing evenly.
The best current evidence comes from clinical neurotechnology. NeuroPace, BrainsWay, Boston Scientific, Flow, Neurolief, Abbott, and several neuromodulation market reports all point to real expansion in reimbursed or near-reimbursed medical categories. This is where the market has revenue, physicians, patients, procedures, and FDA-defined pathways.
BCI is also expanding, but differently. It is growing through funding, trials, regulatory milestones, human implants, AI interest, and geopolitical competition. That is real market formation. But BCI is still not a broad commercial revenue market in June 2026. We should not confuse “massive funding and clinical momentum” with “mass adoption.”
| Question | Verdict | Comment |
|---|---|---|
| Are analysts too bullish? | Yes | Forecasts mostly show 2026 growth, but definitions mix BCI, neuromodulation, diagnostics, and surgical tools. |
| Is BCI funding real demand? | Mixed | Funding is huge, but it mostly prices future clinical markets, not current BCI revenue. |
| Are hospitals using more neurotech? | Yes | BrainsWay, NeuroPace, and Boston Scientific show real provider adoption where workflows already exist. |
| Is depression neurotech breaking out? | Yes | Clinic TMS growth plus FDA-approved at-home depression devices expand access models. |
| Are pain and epilepsy carrying growth? | Yes | Epilepsy RNS and pain neuromodulation remain the most commercially measurable parts of the market. |
| Are payers slowing growth? | Yes | Inspire’s guidance cut and Neuronetics’ treatment-session decline show reimbursement and utilization risk. |
| Are BCI trials moving fast enough? | Mixed | Trial activity is accelerating, but early feasibility studies are not commercial markets. |
| Is FDA activity helping? | Yes | Recent clearances, PMAs, IDEs, and Breakthrough designations create more credible clinical paths. |
| Are incumbents still buying? | Mixed | Boston Scientific and suppliers are expanding, while Nevro shows consolidation after pressure. |
| Is China speeding things up? | Yes | Chinese BCI trials and policy support make the category more competitive and urgent. |
| Is consumer neurotech still smoke? | Mixed | Funding and claims exist, but independent validation and consumer adoption remain weak. |
| Are governments still backing it? | Mixed | Strategic support continues, but NIH BRAIN funding has been volatile. |
| Is AI changing the market? | Yes | Neural data and decoding models are becoming central to company value. |
| Are companies hiring for scale? | Mixed | Top funded platforms are hiring, but there is no broad market-wide hiring boom. |
| Are neurotech companies under pressure? | Yes | Nevro, Inspire, and Neuronetics show real stress despite overall market growth. |
This chart, featured in our neurotechnology market deck, breaks down revenue by region across Europe, Asia, North America, Africa, and South America in the neurotechnology market
OUR METHODOLOGY
The neurotechnology market is difficult to read because its signals are moving at different speeds. BCI funding, FDA activity, hospital adoption, reimbursement pressure, clinical trials, public funding, AI interest, and consumer claims all say something useful, but none of them can answer the market question alone.
We therefore broke the question into the dimensions that most directly shape whether neurotechnology is actually growing: capital formation, clinical adoption, reimbursement, regulatory progress, trial maturity, incumbent strategy, government support, consumer validation, AI-driven data value, and company-level pressure.
For each dimension, we looked at recent signals and weighed them point by point. We prioritized evidence that showed observable market behavior, such as revenue growth, device shipments, guidance changes, FDA approvals, clinical trial movement, acquisitions, and public funding shifts. Forecasts and category estimates were used as context, but not as the core evidence.
This approach also helped separate two different kinds of growth. BCI is clearly gaining momentum through funding, trials, AI interest, and geopolitical competition, but most current commercial evidence still comes from reimbursed clinical neurotechnology. That is why the conclusion is not simply bullish or bearish: the neurotechnology market is growing, but unevenly, with stronger evidence in clinical and reimbursed use cases than in broad BCI or consumer adoption.
Key sources used for this analysis include: Business Wire on Synchron’s $200 million Series D, WIRED on Merge Labs’ $252 million round, NeuroPace’s Q1 2026 results and guidance, BrainsWay’s Q1 2026 financial results and operational highlights, Inspire Medical’s quarterly results, Neuronetics’ Q1 2026 financial and operating results, FDA PMA record for Flow FL-100, Flow Neuroscience’s U.S. product information, FDA PMA record for Neurolief ProlivRx, Neurolief’s FDA PMA announcement, ClinicalTrials.gov on Neuralink’s PRIME study, Paradromics on Connect-One FDA IDE approval, ClinicalTrials.gov on Paradromics’ Connect-One study, Precision Neuroscience on Layer 7 FDA clearance, Business Wire on INBRAIN’s first-in-human graphene neural-interface enrollment, NIH BRAIN Initiative budget data, DARPA’s N3 program, and Resonetics on the Resolution Medical acquisition.
This chart, featured in our neurotechnology market deck, shows annual VC investment in neurotechnology startups
Related blog posts
- How strong is fundraising in the neurotechnology market right now?
- Which companies have raised the most funding in the neurotechnology market?
- Which companies are the most valued in the neurotechnology market?
